Back To Search Results

Well Score

Editor: Scott C. Dulebohn Updated: 10/11/2023 9:58:45 AM

Summary / Explanation

The Wells score for pulmonary embolism is a widely used clinical tool designed to help healthcare providers assess patients suspected of having a pulmonary embolism. Developed by Philip S Wells in 1995, this scoring system offers a structured approach to risk stratification, aiding clinicians in making informed decisions about further diagnostic testing and treatment for this potentially life-threatening condition. This activity aims to provide a comprehensive understanding of the Wells Score, including its calculation and interpretation.[1]

Background

Pulmonary embolism is a critical medical condition characterized by the sudden blockage of one or more pulmonary arteries by a blood clot, often originating from deep vein thrombosis (DVT).[2] Prompt diagnosis is essential to initiate appropriate treatment, as delayed or missed diagnosis can lead to severe complications or even death. The Wells score was developed to improve the accuracy of pulmonary embolism diagnosis and optimize the utilization of diagnostic resources.

Calculation of the Wells Score

The Wells score consists of multiple clinical criteria, and each is assigned a specific value, as described below. The total score is used to classify patients into three risk categories: low, moderate, or high probability of pulmonary embolism.[3]

Wells Score Criteria

  • Clinical signs and symptoms: Clinical signs and symptoms of DVT (eg, leg swelling and pain) = 3 points. An alternative diagnosis is less likely than pulmonary embolism = 3 points.

  • Heart rate: Heart rate more than 100 beats per minute = 1.5 points

  • Immobilization: Immobilization or surgery within the past 4 weeks = 1.5 points

  • Previous DVT or pulmonary embolism = 1.5 points

  • Hemoptysis = 1 point

  • Malignancy: Active malignancy or treatment within the last 6 months = 1 point

Interpretation of the Wells Score

After calculating the Wells score, patients are classified into 1 of 3 risk categories:

  • Low probability (score ≤4 points): Patients with a low Wells score have a low probability of pulmonary embolism. Further diagnostic testing may be unnecessary, and clinical observation or other diagnoses should be considered.

  • Moderate probability (score 4.5-6 points): Patients with a moderate Wells score have an intermediate risk of pulmonary embolism. Further diagnostic evaluation, such as D-dimer testing or imaging studies (eg, computed tomography pulmonary angiography), is typically warranted in this group.

  • High probability (score >6 points): Patients with a high Wells score are highly likely to have pulmonary embolism. Immediate imaging studies are recommended to confirm the diagnosis, and anticoagulation therapy should be initiated promptly.

Importance of D-Dimer Testing

D-dimer testing plays a crucial role in the diagnostic workup of patients suspected of having pulmonary embolism. D-dimer is a fibrin degradation product that is elevated in the blood during ongoing fibrinolysis and the breakdown of blood clots. In the context of suspected pulmonary embolism, D-dimer testing is used as a nonspecific marker to help rule out the presence of a thrombotic event, although it is not specific to pulmonary embolism itself.

Here are key aspects of the diagnostic value of D-dimer testing in patients suspected of having pulmonary embolism:[4][5]

  • Sensitivity for pulmonary embolism: D-dimer testing is highly sensitive but not specific. A negative D-dimer result is particularly valuable for ruling out pulmonary embolism, as a low D-dimer level is associated with a low probability of a thrombotic event. The high sensitivity means a negative D-dimer result can be relied upon to exclude pulmonary embolism in low to moderate-risk patients, reducing the need for more invasive and expensive imaging studies.

  • Role in risk stratification: D-dimer testing is often used in conjunction with clinical prediction models, such as the Wells score, to stratify patients into risk categories. In patients with a low pre-test probability of pulmonary embolism, a negative D-dimer result can effectively rule out the condition without the need for further imaging studies. In those with an intermediate or high pre-test probability, a positive D-dimer result requires further investigation with imaging studies to confirm or exclude the diagnosis.

  • Considerations for special populations: D-dimer levels naturally increase with age, and other conditions, such as inflammation, infection, trauma, surgery, and certain malignancies, can also elevate D-dimer levels. Therefore, clinical judgment is essential when interpreting D-dimer results in specific patient populations.

  • Limitations and false positives: D-dimer testing has limitations, and a positive result does not confirm the diagnosis of pulmonary embolism. Many conditions other than pulmonary embolism can lead to elevated D-dimer levels. False positives may occur in situations such as recent surgery, trauma, or other thrombotic events. Therefore, clinical correlation and further diagnostic evaluation are necessary in cases of positive D-dimer results.

  • Role in exclusion protocol: Many clinical algorithms and guidelines incorporate D-dimer testing into exclusion protocols for suspected pulmonary embolism. Clinicians may safely exclude pulmonary embolism without further imaging studies in patients with a low pre-test probability and a negative D-dimer result.

  • Serial testing: Serial D-dimer testing may be useful in certain situations, especially when the initial result is inconclusive. Monitoring changes in D-dimer levels over time can offer additional insights into the likelihood of ongoing thrombosis.

The Wells score for pulmonary embolism has become an indispensable tool in clinical practice, aiding clinicians in determining the most suitable diagnostic and treatment pathways for patients with suspected pulmonary embolism. By categorizing patients based on their risk levels, the Wells score facilitates the optimal allocation of limited healthcare resources and minimizes unnecessary radiation exposure from imaging studies. This scoring system not only improves the accuracy of pulmonary embolism diagnosis but also promotes the efficient utilization of healthcare resources.

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

References


[1]

Freund Y, Cohen-Aubart F, Bloom B. Acute Pulmonary Embolism: A Review. JAMA. 2022 Oct 4:328(13):1336-1345. doi: 10.1001/jama.2022.16815. Epub     [PubMed PMID: 36194215]


[2]

Kline JA. Diagnosis and Exclusion of Pulmonary Embolism. Thrombosis research. 2018 Mar:163():207-220. doi: 10.1016/j.thromres.2017.06.002. Epub 2017 Jun 7     [PubMed PMID: 28683951]


[3]

Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet (London, England). 2021 Jul 3:398(10294):64-77. doi: 10.1016/S0140-6736(20)32658-1. Epub 2021 May 10     [PubMed PMID: 33984268]


[4]

Kearon C, de Wit K, Parpia S, Schulman S, Afilalo M, Hirsch A, Spencer FA, Sharma S, D'Aragon F, Deshaies JF, Le Gal G, Lazo-Langner A, Wu C, Rudd-Scott L, Bates SM, Julian JA, PEGeD Study Investigators. Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability. The New England journal of medicine. 2019 Nov 28:381(22):2125-2134. doi: 10.1056/NEJMoa1909159. Epub     [PubMed PMID: 31774957]


[5]

Chopard R, Albertsen IE, Piazza G. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. JAMA. 2020 Nov 3:324(17):1765-1776. doi: 10.1001/jama.2020.17272. Epub     [PubMed PMID: 33141212]